Active CMV disease does not always correlate with viral load detection.

Area of Science:

• Hematology
• Infectious Diseases
• Transplantation Immunology

Background:

• Cytomegalovirus (CMV) reactivation is a significant complication following stem cell transplantation (SCT).
• Preemptive ganciclovir therapy guided by quantitative CMV real-time polymerase chain reaction (RT-PCR) is increasingly used for high-risk SCT patients.
• Limited data exist on the precise role and limitations of this preemptive strategy in SCT settings.

Purpose of the Study:

• To evaluate the effectiveness and limitations of quantitative CMV RT-PCR for guiding preemptive ganciclovir therapy in SCT recipients.
• To determine the CMV reactivation rates and the incidence of CMV end-organ disease in a large cohort of SCT patients.
• To assess the reliability of CMV RT-PCR in diagnosing CMV end-organ disease.

Main Methods:

• A retrospective single-center study analyzed 577 consecutive SCT patients (172 allogeneic, 405 autologous) over 5 years.
• Quantitative CMV RT-PCR was performed weekly, with treatment initiated upon two consecutive positive results or a high viral load (>1000 copies/ml).
• Monitoring duration varied based on SCT type: until immunosuppression cessation for allogeneic and 30 days post-SCT for autologous.

Main Results:

• The overall CMV reactivation rate was 30% in allogeneic SCT recipients, reaching 72% in high-risk (recipient positive) patients.
• CMV end-organ disease occurred in 1% of patients (eight cases); four were CMV RT-PCR negative at diagnosis, with three remaining negative throughout.
• Three CMV-related deaths were recorded.

Conclusions:

• Quantitative CMV RT-PCR-guided preemptive treatment is supported by these data for SCT patients.
• A negative CMV RT-PCR result should not exclude the possibility of CMV end-organ disease in symptomatic patients.
• Further refinement of CMV monitoring and diagnostic approaches in SCT is warranted.